MedTrace Logo

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

NCT00820768 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-04-11

No results posted yet for this study

Summary

To determine MTD and DLT of ABI-010 given weekly every three weeks followed by one week of rest (Cycle 1). Determine MLD and DLT in combination with ABI-007; to characterize the toxicities of ABI-010 alone and in combination with ABI-007.

Conditions

Interventions

DRUG

ABI-010

17-AAG and ABI-007

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Henry C. Pitot, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-01
Primary Completion
2013-04-01
Completion
2014-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00820768 on ClinicalTrials.gov